Reports Q2 revenue $19.5M, consensus $18.4M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
- Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
- Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics